Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Flortaucipir PET vs Autopsy Tau Pathology
NCT02516046Phase 3Completed
- Sponsor
- Avid Radiopharmaceuticals
- Start
- Sep 2015
- Primary completion
- Jun 2018
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, open-label, single-arm trial of flortaucipir in Alzheimer's disease (AD), sponsored by Avid Radiopharmaceuticals. Primary endpoints: Diagnostic Performance of Individual Readers (NFT Score) and Diagnostic Performance of Individual Readers (NIA-AA Autopsy Diagnosis). Started Sep 2015; status: completed.
02
Drugs
flortaucipir
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT02516046.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02516046.